Breaking News

FDA examiners report incoherent data for Rexulti in the SSPT

(Medage today) – The question of whether Brexpiprazole (Rexulti) is effective because the extra treatment for post -traumatic stress disorder (SSPT) will be debated by the FDA Consultative Committee of the FDA on Friday. The atypical antipsychotic is being examined as …

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button